Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

BACKGROUND: The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial(1) prospectively obtained serum and tumor core biopsies and randomized 255 chemorefractory non–small-cell lung cancer (NSCLC) patients into four phase II trials: erlotinib, erlotinib-bexarotene, van...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Oncol
Hlavní autoři: Tsao, Anne S., Liu, Suyu, Lee, J. Jack, Alden, Christine M., Blumenschein, George R., Herbst, Roy, Davis, Suzanne E., Kim, Edward, Lippman, Scott, Heymach, John, Tran, Hai, Tang, XiMing, Wistuba, Ignacio, Hong, Waun Ki
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118909/
https://ncbi.nlm.nih.gov/pubmed/23584298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31828d08ae
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky